Latest Insider Transactions at Schrodinger, Inc. (SDGR)
This section provides a real-time view of insider transactions for Schrodinger, Inc. (SDGR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Schrodinger, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Schrodinger, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
12,040
-48.62%
|
$602,000
$50.0 P/Share
|
|
Jun 30
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,040
+32.72%
|
$204,680
$17.0 P/Share
|
|
Jun 15
2023
|
Rosana Kapeller Libermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Jeffrey Chodakewitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Michael Lynton Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Arun Oberoi Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Gary Sender Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Richard Friesner Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+1.21%
|
-
|
|
Jun 15
2023
|
Gary L Ginsberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
May 23
2023
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
10,000
-17.43%
|
$400,000
$40.06 P/Share
|
|
May 23
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
7,960
-38.49%
|
$318,400
$40.01 P/Share
|
|
May 23
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,960
+27.79%
|
$31,840
$4.34 P/Share
|
|
May 22
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
15,000
-54.11%
|
$525,000
$35.04 P/Share
|
|
May 22
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+17.89%
|
$45,000
$3.71 P/Share
|
|
May 22
2023
|
Nancy Thornberry Director |
SELL
Open market or private sale
|
Direct |
14,850
-100.0%
|
$519,750
$35.0 P/Share
|
|
May 22
2023
|
Nancy Thornberry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,850
+50.0%
|
$163,350
$11.52 P/Share
|
|
Feb 09
2023
|
Jenny Herman SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+49.99%
|
-
|
|
Feb 09
2023
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
BUY
Grant, award, or other acquisition
|
Direct |
8,170
+12.46%
|
-
|
|
Feb 09
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Grant, award, or other acquisition
|
Direct |
7,590
+37.37%
|
-
|
|
Feb 09
2023
|
Robert Lorne Abel Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,545
+50.0%
|
-
|
|
Feb 02
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
25,000
-82.97%
|
$675,000
$27.26 P/Share
|
|
Feb 02
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+35.8%
|
$50,000
$3.0 P/Share
|
|
Jan 04
2023
|
Ramy Farid President & CEO |
SELL
Open market or private sale
|
Direct |
66,886
-26.61%
|
$1,203,948
$18.28 P/Share
|
|
Jan 04
2023
|
Ramy Farid President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
66,886
+21.02%
|
$66,886
$1.2 P/Share
|
|
Aug 11
2022
|
Nancy Thornberry Director |
SELL
Open market or private sale
|
Direct |
4,950
-100.0%
|
$173,250
$35.0 P/Share
|
|
Aug 11
2022
|
Nancy Thornberry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,950
+50.0%
|
$54,450
$11.52 P/Share
|
|
Dec 13
2021
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
15,601
-93.91%
|
$561,636
$36.54 P/Share
|
|
Dec 13
2021
|
Robert Lorne Abel Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,601
+50.0%
|
$265,217
$17.0 P/Share
|
|
Oct 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
1,393
-100.0%
|
$76,615
$55.75 P/Share
|
|
Oct 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
1,393
+50.0%
|
$5,572
$4.34 P/Share
|
|
Sep 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
1,394
-100.0%
|
$85,034
$61.13 P/Share
|
|
Sep 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
1,394
+50.0%
|
$5,576
$4.34 P/Share
|
|
Sep 13
2021
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
15,602
-68.65%
|
$951,722
$61.62 P/Share
|
|
Sep 13
2021
|
Robert Lorne Abel Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,602
+50.0%
|
$265,234
$17.0 P/Share
|
|
Sep 02
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
3,874
-100.0%
|
$247,936
$64.62 P/Share
|
|
Sep 02
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,874
+50.0%
|
$15,496
$4.34 P/Share
|
|
Sep 01
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
1,700
-100.0%
|
$108,800
$64.53 P/Share
|
|
Sep 01
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+50.0%
|
$6,800
$4.34 P/Share
|
|
Aug 16
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
37,738
-78.74%
|
$2,151,066
$57.8 P/Share
|
|
Aug 16
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
37,738
+30.27%
|
$301,904
$8.19 P/Share
|
|
Aug 02
2021
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
12,000
-32.42%
|
$816,000
$68.27 P/Share
|
|
Jul 19
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
63,061
-0.26%
|
$4,225,087
$67.64 P/Share
|
|
Jul 16
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,000
-0.16%
|
$1,914,000
$66.94 P/Share
|
|
Jul 15
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
59,358
-0.32%
|
$3,917,628
$66.63 P/Share
|
|
Jul 14
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
5,574
-78.34%
|
$379,032
$68.44 P/Share
|
|
Jul 14
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,574
+50.0%
|
$22,296
$4.34 P/Share
|
|
Jul 14
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,051
-0.18%
|
$2,315,468
$68.45 P/Share
|
|
Jul 13
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,213
-0.16%
|
$3,636,123
$71.64 P/Share
|
|
Jul 12
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,930
-0.11%
|
$1,569,750
$75.22 P/Share
|